Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine ... when they really need it,” Duncan McKechnie, head of North America commercial at Vertex, said.

Better understanding of the complex relationship between mind and body may provide new treatment strategies for chronic pain, ...

I think Nvidia has massive growth prospects, but a sharp economic downturn would ... a non-opioid drug for alleviating acute ...

Heat and cold therapies as well as painkillers may relieve pain, as well as physical therapies or steroid injections. FEELS LIKE: Sharp pain in ... one knee towards your head, with your arms ...

Hip Osteoarthritis Another common cause of groin pain is osteoarthritis (OA) of the hip. OA in the hip occurs when the smooth cartilage on the end of the ball (femoral head) and socket ... typically ...

VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Overall, if the anticipated decrease in pain intensity is confirmed, it would reinforce Vertex’s position in the market and justify the Buy rating. In another report released yesterday, Wells Fargo ...

E-VIPR allowed Vertex to test many more potential compounds and with greater efficiency. “The level of selectivity that I believe is required to achieve pain-signal inhibition without effecting ...

Vertex is a global biotechnology company that ... including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 ...

The continued support comes after Vertex presented more detailed Phase 3 information on its non-opioid pain medication, Suzetrigine, at the Anesthesiology Meeting. The new data provided insights ...